<!DOCTYPE html>
<html>
<head>
    <title>BREAKING: Federal Register: Expedited Program for Serious Conditions-Accelerated Approval of Drugs and Biologics; Draft Guidance for Industry; Availability</title>
    <meta charset="UTF-8">
    <style>
        body { font-family: Georgia, serif; max-width: 800px; margin: 0 auto; padding: 20px; }
        h1 { border-bottom: 2px solid #333; }
        .breaking { background: #fff3cd; border-left: 4px solid #dc3545; padding: 15px; }
        .source { background: #f8f9fa; padding: 10px; margin-top: 20px; font-size: 0.9em; }
        .timestamp { color: #666; }
    </style>
</head>
<body>
    <h1>BREAKING: Federal Register: Expedited Program for Serious Conditions-Accelerated Approval of Drugs and Biologics; Draft Guidance for Industry; Availability</h1>
    <p class="timestamp">Published: 2024-12-06 | Source: Federal Register</p>
    <div class="breaking">
        <p><strong>The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Expedited Program for Serious Conditions--Accelerated Approval of Drugs and Biologics." Accelerated approval is one of FDA's expedited programs intended to facilitate and expedite development and review of certain drugs and biological products for serious or life-threatening conditions. This guidance provides information on FDA's policies and procedures for the accelerated a...</strong></p>
    </div>
    <h2>Document Details</h2>
    <p><strong>Document Type:</strong> Notice</p>
    <p><strong>Agency:</strong> Health and Human Services Department, Food and Drug Administration</p>
    <p><strong>Document Number:</strong> 2024-28392</p>
    <p><strong>Publication Date:</strong> 2024-12-06</p>
    <h2>Official Source</h2>
    <p>Read the full document at: <a href="https://www.federalregister.gov/documents/2024/12/06/2024-28392/expedited-program-for-serious-conditions-accelerated-approval-of-drugs-and-biologics-draft-guidance">https://www.federalregister.gov/documents/2024/12/06/2024-28392/expedited-program-for-serious-conditions-accelerated-approval-of-drugs-and-biologics-draft-guidance</a></p>
    <div class="source"><strong>Source:</strong> Federal Register - 2024-28392</div>
    <p><a href="index.html">Back to Breaking News Wire</a></p>
</body>
</html>
